Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma

Table 2 Univariate log-rank analysis for important clinicopathological and phosphatidylinositol 3-kinase CB expression

Parameter	DSS			LRFS			MeFS
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
Sex	1.482	0.654-3.356	0.346	0.970	0.483-1.945	0.931	0.586	0.219-1.570	0.288
Age	0.908	0.377-2.186	0.830	1.491	0.749-2.970	0.25602	1.947	0.808-4.693	0.138
TH	0.737	0.320-1.698	0.473	1.096	0.412-2.915	0.854	0.726	0.218-2.413	0.601
PreTNM	0.976	0.309-3.084	0.967	0.809	0.293-2.237	0.683	0.507	0.145-1.771	0.287
BMI	1.385	0.774-2.480	0.272	1.180	0.732-1.903	0.497	1.106	0.569-2.151	0.766
LVI	2.018	0.687-5.927	0.202	1.106	0.366-3.340	0.858	0.851	0.214-3.376	0.818
Diff.	1.065	0.470-2.415	0.880	0.460	0.203-1.041	0.062	0.438	0.128-1.494	0.187
ypT	1.200	0.546-2.640	0.650	0.971	0.537-1.756	0.923	1.067	0.488-2.332	0.872
ypN	0.839	0.498-1.414	0.510	2.926	1.816-4.713	0.000	2.442	1.275-4.674	0.007
TRG	2.337	1.064-5.136	0.035	1.981	1.012-3.877	0.046	2.755	1.052-7.215	0.039
PIK3CB	1.685	0.727-3.909	0.224	2.228	0.801-6.202	0.125	1.828	0.397-8.411	0.439

DSS: Disease-specific survival; LRFS: Local recurrence-free survival; MeFS: Metastasis-free survival; PIK3: Phosphatidylinositol 3-kinase; TH: Tumor height; BMI: Body mass index; LVI: Lymph vessel invasion; TRG: Tumor regression grade.